- Home
- GTN vs ATXS Comparison
GTN vs ATXS Comparison
Compare GTN & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- ATXS
- Stock Information
- Founded
- GTN 1897
- ATXS 2008
- Country
- GTN United States
- ATXS United States
- Employees
- GTN N/A
- ATXS N/A
- Industry
- GTN Broadcasting
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- GTN Industrials
- ATXS Health Care
- Exchange
- GTN Nasdaq
- ATXS Nasdaq
- Market Cap
- GTN 491.0M
- ATXS 401.2M
- IPO Year
- GTN N/A
- ATXS 2015
- Fundamental
- Price
- GTN $3.36
- ATXS $4.94
- Analyst Decision
- GTN Strong Buy
- ATXS Strong Buy
- Analyst Count
- GTN 3
- ATXS 5
- Target Price
- GTN $6.33
- ATXS $26.60
- AVG Volume (30 Days)
- GTN 1.4M
- ATXS 373.0K
- Earning Date
- GTN 05-08-2025
- ATXS 05-08-2025
- Dividend Yield
- GTN 9.82%
- ATXS N/A
- EPS Growth
- GTN N/A
- ATXS N/A
- EPS
- GTN 3.36
- ATXS N/A
- Revenue
- GTN $3,644,000,000.00
- ATXS N/A
- Revenue This Year
- GTN N/A
- ATXS N/A
- Revenue Next Year
- GTN $14.86
- ATXS N/A
- P/E Ratio
- GTN $0.97
- ATXS N/A
- Revenue Growth
- GTN 11.06
- ATXS N/A
- 52 Week Low
- GTN $2.91
- ATXS $3.56
- 52 Week High
- GTN $7.41
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- GTN 33.99
- ATXS 49.98
- Support Level
- GTN $3.13
- ATXS $3.56
- Resistance Level
- GTN $3.47
- ATXS $4.18
- Average True Range (ATR)
- GTN 0.24
- ATXS 0.43
- MACD
- GTN -0.06
- ATXS 0.10
- Stochastic Oscillator
- GTN 9.84
- ATXS 80.50
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.